The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
What is the Objective of the Mass Balance Study? A Retrospective Analysis of Data in Animal and Human Excretion Studies Employing Radiolabeled Drugs
Abstract
Mass balance excretion studies in laboratory animals and humans using radiolabeled compounds represent a standard part of the development process for new drugs. From these studies, the total fate of drug-related material is obtained: mass balance, routes of excretion, and, with additional analyses, metabolic pathways. However, rarely does the mass balance in radiolabeled excretion studies truly achieve 100% recovery. Many definitions of cutoff criteria for mass balance that identify acceptable versus unacceptable recovery have been presented as ad hoc statements without a strong rationale. To address this, a retrospective analysis was undertaken to explore the overall performance of mass balance studies in both laboratory animal species and humans using data for 27 proprietary compounds within Pfizer and extensive review of published studies. The review has examined variation in recovery and the question of whether low recovery was a cause for concern in terms of drug safety. Overall, mean recovery was greater in rats and dogs than in humans. When the circulating half-life of total radioactivity is greater than 50 h, the recovery tends to be lower. Excretion data from the literature were queried as to whether drugs linked with toxicities associated with sequestration in tissues or covalent binding exhibit low mass balance. This was not the case, unless the sequestration led to a long elimination half-life of drug-related material. In the vast majority of cases, sequestration or concentration of drug-related material in an organ or tissue was without deleterious effect and, in some cases, was related to the pharmacological mechanism of action. Overall, from these data, recovery of radiolabel would normally be equal to or greater than 90%, 85%, and 80% in rat, dog, and human, respectively. Since several technical limitations can underlie a lack of mass balance and since mass balance data are not sensitive indicators of the potential for toxicity arising via tissue sequestration, absolute recovery in humans should not be used as a major decision criteria as to whether a radiolabeled study has met its objectives. Instead, the study should be seen as an integral part of drug development answering four principal questions: 1) Is the proposed clearance mechanism sufficiently supported by the identities of the drug-related materials in excreta, so as to provide a complete understanding of clearance and potential contributors to interpatient variability and drug-drug interactions? 2) What are the drug-related entities present in circulation that are the active principals contributing to primary and secondary pharmacology? 3) Are there findings (low extraction recovery of radiolabel from plasma, metabolite structures indicative of chemically reactive intermediates) that suggest potential safety issues requiring further risk assessment? 4) Do questions 2 and 3 have appropriate preclinical support in terms of pharmacology, safety pharmacology, and toxicology? Only if one or more of these four questions remain unanswered should additional mass balance studies be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UV-induced DNA damage and melanin content in human skin differing in racial/ethnic origin
Tadokoro, T., Kobayashi, N., Zmudzka, B. Z., Ito, S., Wakamatsu, K., Yamaguchi, Y., Korossy, K. S., Miller, S. A., Beer, J. Z., & Hearing, V. J. (2003) · The FASEB Journal · doi:10.1096/fj.02-0865fje · Cited by 378
Metabolism, Excretion, and Pharmacokinetics of Rosuvastatin in Healthy Adult Male Volunteers
Martin, P. D., Warwick, M. J., Dane, A. L., Hill, S. J., Giles, P. B., Phillips, P. J., & Lenz, E. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80336-3 · Cited by 286
Dose-dependent pharmacokinetics of acetaminophen: Evidence of glutathione depletion in humans
Slattery, J. T., Wilson, J. M., Kalhorn, T. F., & Nelson, S. D. (1987) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1987.50 · Cited by 143
Chloroquine causes lysosomal dysfunction in neural retina and RPE: implications for retinopathy
Mahon, G. J., Anderson, H. R., Gardiner, T. A., McFarlane, S., Archer, D. B., & Stitt, A. W. (2004) · Current Eye Research · doi:10.1076/ceyr.28.4.277.27835 · Cited by 108
Cited by
Deuterium‐ and Tritium‐Labelled Compounds: Applications in the Life Sciences
Atzrodt, J., Derdau, V., Kerr, W. J., & Reid, M. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201704146 · Cited by 810
Using Deuterium in Drug Discovery: Leaving the Label in the Drug
Gant, T. G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4007998 · Cited by 764
Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans
Raghavan, N., Frost, C. E., Yu, Z., He, K., Zhang, H., Humphreys, W. G., Pinto, D., Chen, S., Bonacorsi, S., Wong, P. C., et al. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023143 · Cited by 612
Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)
Varma, M. V., Steyn, S. J., Allerton, C., & El-Kattan, A. F. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1749-4 · Cited by 334
Dahlgren, D., & Lennernäs, H. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11080411 · Cited by 255
Metadata
- Authors
- Roffey, S. J., Obach, R. S., Gedge, J. I., & Smith, D. A.
- Venue
- Drug Metabolism Reviews
- Publisher
- Informa UK Limited
- Published
- 2007-01
- Volume
- 39
- Issue
- 1
- Pages
- 17-43
- ISSN
- 0360-2532 (ISSN-L)
- 1097-9883
- OpenAlex
- W2133849435
- Cited by
- 239
- References
- 4
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: What is the Objective of the Mass Balance Study? A Retrospective Analysis of Data in Animal and Human Excretion Studies Employing Radiolabeled Drugs. https://app.cochat.ai/papers/10.1080/03602530600952172
- The paper
- Roffey, S. J., Obach, R. S., Gedge, J. I., & Smith, D. A. (2007). What is the Objective of the Mass Balance Study? A Retrospective Analysis of Data in Animal and Human Excretion Studies Employing Radiolabeled Drugs. Drug Metabolism Reviews. https://doi.org/10.1080/03602530600952172
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.